Home > Medicine > Other > Volume-5 > Issue-3 > Diagnostic Biomarker Candidates Including NT5DC2 for Human Uterine Mesenchymal Tumors

Diagnostic Biomarker Candidates Including NT5DC2 for Human Uterine Mesenchymal Tumors

Call for Papers

Volume-8 | Issue-6

Last date : 27-Dec-2024

Best International Journal
Open Access | Peer Reviewed | Best International Journal | Indexing & IF | 24*7 Support | Dedicated Qualified Team | Rapid Publication Process | International Editor, Reviewer Board | Attractive User Interface with Easy Navigation

Journal Type : Open Access

First Update : Within 7 Days after submittion

Submit Paper Online

For Author

Research Area


Diagnostic Biomarker Candidates Including NT5DC2 for Human Uterine Mesenchymal Tumors


Takuma Hayashi | Kenji Sano | Tomoyuki Ichimura | Susumu Tonegawa | Nobuo Yaegashi | Ikuo Konishi



Takuma Hayashi | Kenji Sano | Tomoyuki Ichimura | Susumu Tonegawa | Nobuo Yaegashi | Ikuo Konishi "Diagnostic Biomarker Candidates Including NT5DC2 for Human Uterine Mesenchymal Tumors" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-3, April 2021, pp.60-64, URL: https://www.ijtsrd.com/papers/ijtsrd38686.pdf

Unfortunately, uterine leiomyosarcoma still has a poor prognosis. The National Cancer Institute reported that the median overall survival (mOS) at stage I to stage IV of leiomyosarcoma was 31 months. Norwegian reports show that mOS of uterine leiomyosarcoma is as poor as eight years at stage I, four years at stage II, two years at stage III, and one year at stage IV. Preoperative diagnosis of uterine leiomyosarcoma is difficult in clinical practice. Treated as "uterine leiomyoma", however, tumors are often differentially diagnosed from uterine leiomyosarcoma by pathological diagnosis with hysterectomy or myomectomy. Histopathological diagnosis may result in a diagnosis of smooth muscle tumor of unmalignant potential (STUMP), and leiomyoma with bizarre nuclei that cannot be declared as malignant or benign. In about half of stage I patients, uterine leiomyosarcoma recurs. However, at present, no anticancer drug that has been shown to be effective in preventing postoperative recurrence has not been established. For this reason, we monitor patients without postoperative treatment, and start clinical treatment when recurrence is confirmed. Uterine leiomyomas, which occur in about 70% of women aged 40 and over in Japan and overseas, are benign tumors, but are extremely difficult to distinguish from uterine leiomyosarcoma. Although progress in diagnostic imaging such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography- Computed Tomography (PET-CT) is remarkable, uterine leiomyosarcoma is difficult to distinguish from other uterine mesenchymal tumors. No differential biomarker has been identified for uterine other uterine mesenchymal tumors and uterine leiomyosarcoma in surgical pathological diagnosis or clinical examination. This review describes the current diagnosis and treatment for uterine sarcoma, including new trends in the search for biomarker candidates for uterine leiomyosarcoma.

leiomyosarcoma, leiomyoma, mesenchymal tumor, LMP2/ß1i


IJTSRD38686
Volume-5 | Issue-3, April 2021
60-64
IJTSRD | www.ijtsrd.com | E-ISSN 2456-6470
Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

International Journal of Trend in Scientific Research and Development - IJTSRD having online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International Journal which provides rapid publication of your research articles and aims to promote the theory and practice along with knowledge sharing between researchers, developers, engineers, students, and practitioners working in and around the world in many areas like Sciences, Technology, Innovation, Engineering, Agriculture, Management and many more and it is recommended by all Universities, review articles and short communications in all subjects. IJTSRD running an International Journal who are proving quality publication of peer reviewed and refereed international journals from diverse fields that emphasizes new research, development and their applications. IJTSRD provides an online access to exchange your research work, technical notes & surveying results among professionals throughout the world in e-journals. IJTSRD is a fastest growing and dynamic professional organization. The aim of this organization is to provide access not only to world class research resources, but through its professionals aim to bring in a significant transformation in the real of open access journals and online publishing.

Thomson Reuters
Google Scholer
Academia.edu

ResearchBib
Scribd.com
archive

PdfSR
issuu
Slideshare

WorldJournalAlerts
Twitter
Linkedin